Status:

COMPLETED

MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva

Lead Sponsor:

Fondation pour l'accueil et l'hébérement des personnes âgées

Collaborating Sponsors:

University Hospital, Geneva

Conditions:

Dementia with Behavioral Disturbance

Eligibility:

All Genders

55+ years

Phase:

PHASE2

PHASE3

Brief Summary

The behavioral and psychological symptoms of dementia affect up to 80% of long-term facilities residents with severe dementia. They seriously alter the quality of life of patients, relatives, and heal...

Detailed Description

The study design is a placebo-controlled cross-over trial. The patients, the relatives, the health care professionals, and the study staff will be blinded. Medical cannabis treatment is a cannabis oi...

Eligibility Criteria

Inclusion

  • Patients with severe dementia from different origins (Alzheimer's disease, vascular, mixed)
  • Clinical Dementia Rating ≥3
  • Persisting behavior problems (Neuropsychiatric Inventory \[NPI\] score \> 10) notwithstanding optimal conventional treatment
  • SARS-CoV-2 recovered for two weeks, or SARS-CoV-2 fully vaccinated
  • Consent obtained from the representative in the medical field according to art 378 Swiss Civil Code (SCC)

Exclusion

  • Severe organ deficiency such as cardiac, pulmonary, hepatic, renal insufficiency, or unstable heart rhythm
  • Symptomatic orthostatic hypotension
  • Major changes or instability of psychotropic medication in the week preceding the study enrolment
  • Having taken THC and/or CBD in the 7 days before enrolment
  • Hemoglobin \< 10 g/dl
  • Severe kidney failure defined by cockcroft calculation \<30 ml/mn
  • Alanine aminotransferase and aspartate aminotransferase \> 3x upper limit of normal
  • Any other medical conditions that would prevent participation in the whole study protocol.

Key Trial Info

Start Date :

September 29 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 29 2024

Estimated Enrollment :

27 Patients enrolled

Trial Details

Trial ID

NCT05432206

Start Date

September 29 2023

End Date

November 29 2024

Last Update

December 17 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

FAHPA

Geneva, Canton of Geneva, Switzerland, 1206